<DOC>
	<DOCNO>NCT00632333</DOCNO>
	<brief_summary>The purpose study evaluate safety immune response multiple peptide ( URLC10 , TTK , KOC1 VEGFR1 , VEGFR2 ) emulsify Montanide ISA51 combination chemotherapy ( CDDP , 5-FU ) plus radiation therapy treat patient unresectable , advanced recurrent esophageal cancer .</brief_summary>
	<brief_title>Combination Chemoradiation Therapy Epitope Peptide Vaccine Therapy Treating Patients With Esophageal Cancer</brief_title>
	<detailed_description>Up-regulated ling cancer 10 ( URLC10 ) , TTK protein kinase ( TTK ) K homology domain contain protein express cancer ( KOC1 ) identify new target tumor associate antigen use cDNA microarray technology combine expression profile normal cancer tissue . Furthermore , anti-angiogenic therapy consider one promising approach treat cancer . Vascular endothelial growth factor receptor 1 ( VEGFR1 ) vascular endothelial growth factor receptor 2 ( VEGFR2 ) essential target tumor angiogenesis . Epitope peptides target able induce cytotoxic T lymphocyte ( CTL ) restrict HLA-A *2402 vivo . On hand , chemotherapy ( CDDP , 5-FU ) plus radiation therapy standard treatment unresectable advanced esophageal cancer . In clinical trial , evaluate safety immune response different dos multiple peptide ( URLC10 , TTK , KOC1 , VEGFR1 , VEGFR 2 ) emulsify Montanide ISA 51 combination chemotherapy ( CDDP , 5-FU ) plus radiation therapy treat patient unresectable , advanced recurrent esophageal cancer .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1 . Patients must unresectable , locally advanced , recurrent metastatic disease esophageal cancer . 2. measurable disease CT scan 3 . ECOG performance status 0 2 4 . Expected survival lease 3months 5 . Patients must HLAA2402 6 . Laboratory value follow : WBC &gt; 2000/mm3 , Platelet count &gt; 75000/mm3 , Total bilirubin &lt; 1.5 x institutional normal upper limit , Creatinine &lt; 1.5 x institutional normal upper limit , AST . ALT . ALP &lt; 2.5 x institutional normal upper limit 7 . Able willing give valid write informed consent 1 . Pregnancy ( woman childbearing potential : Refusal inability use effective mean contraception ) 2 . Breastfeeding 3 . Active uncontrolled infection 4 . Prior chemotherapy , radiation therapy immunotherapy within 4 week 5 . Concurrent treatment steroid immunosuppressing agent 6 . Patient peptic ulcer disease 7 . Active uncontrolled malignancy 8 . Other malignancy within 5 year prior entry study , expect treat nonmelanoma skin cancer cervical carcinoma situ 9 . Disease central nervous system 10 . Decision unsuitableness principal investigator physicianincharge</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Epitope peptide</keyword>
	<keyword>Vaccination</keyword>
	<keyword>Chemoradiation</keyword>
	<keyword>Esophageal cancer</keyword>
</DOC>